Diltiazem vs. Metoprolol in the Acute Management of AF in Patients With HFrEF
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
Atrial fibrillation (AF) is the most common arrhythmia, accounting for one third of all
hospital admissions and 1% of all emergency department visits (ED). Approximately 65% of
those presenting to the ED with AF are admitted. There are also numerous reasons for patients
to get AF with rapid ventricular rate (AF RVR) during hospitalization. In the acute setting
these patients are often treated with diltiazem, a non-dihydropyridine calcium channel
blocker (ND CCB), or metoprolol, a beta blocker (BB). Non-dihydropyridine calcium channel
blocker (diltiazem and verapamil) use is considered harmful and national guidelines recommend
against use in patients with decompensated heart failure (HF). This recommendation is based
on studies with long-term treatment. The purpose of this study is to assess the difference
between metoprolol and diltiazem for the acute treatment of AF RVR in patients with HF with
reduced ejection fraction (HFrEF).
Details
Lead Sponsor:
RaeAnn Hirschy
Collaborators:
Gary Peksa, PharmD, BCPS Joshua DeMott, PharmD, BCPS, BCCCP Kimberly Ackerbauer, PharmD, BCPS, BCCCP Paul O'Donnell, PharmD, BCPS, BCCCP